熱門資訊> 正文
据英国《金融时报》报道，辉瑞以73亿美元收购减肥药制造商Metsera
2025-09-22 13:45
- Pfizer (NYSE:PFE) is closing in on a potential $7.3 billion takeover of weight-loss drug maker (NASDAQ:MTSR) Metsera, the Financial Times reported on Sunday.
- The U.S. pharma giant looks to buy New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the report said, adding that the announcement could come as early as Monday, unless deal talks fall through.
- Talks to acquire Metsera (NASDAQ:MTSR) come just months after the biotech firm's blockbuster debut on Nasdaq.
- The $47.50-per-share offer reflects a roughly 42.5% premium over Metsera's Friday closing price of $33.32, which pegged its market value at about $3.5 billion.
More on Pfizer, Metsera
- Pfizer: Dividend Cushion Ratio Brings Yield Sustainability Into Question
- Pfizer: Cheap Doesn't Mean Good
- Why I Sold Pfizer To Buy Novo Nordisk
- Trump considering website for consumers to buy discounted prescription drugs - report
- CDC vaccines panel votes unanimously to change COVID-19 vaccine recommendation
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
